Vertex’s povetacicept reduced proteinuria by 49.8% versus placebo at Week 36 in the Phase 3 RAINIER trial in IgA nephropathy. FDA decision expected November 30, 2026.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
Vertex Pharmaceuticals announced on October 23, 2026, the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM) and their presentation at the American Society of Nephrology (ASN) Kidney Week 2026. The Week 36 interim analysis met the trial’s primary endpoint and both secondary endpoints in adults with immunoglobulin A nephropathy (IgAN). The findings support the company’s pending application for accelerated approval, although longer-term kidney function data remain outstanding.
RAINIER Trial Design and Interim Analysis
RAINIER (NCT06564142) is a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating povetacicept 80 mg administered subcutaneously every four weeks alongside standard of care. The study enrolled 605 adults, including 557 in the main cohort and 48 in an exploratory cohort.
The prespecified interim efficacy analysis included 199 participants from the main cohort, with 131 receiving povetacicept and 68 receiving placebo. The primary endpoint was the percentage change from baseline in 24-hour urine protein-to-creatinine ratio (UPCR) at Week 36.
The final analysis will assess total estimated glomerular filtration rate (eGFR) slope through Week 104. The trial remains blinded while participants continue follow-up.
Proteinuria Reduction and Secondary Endpoints
Povetacicept reduced 24-hour UPCR by 52.0% from baseline at Week 36, corresponding to a statistically significant 49.8% reduction versus placebo (P<0.0001). The treatment effect was consistent across prespecified demographic, clinical and regional subgroups, including a 54.2% reduction versus placebo in North America.
At Week 36, 42.2% of participants receiving povetacicept achieved a UPCR below 0.5 g/g, compared with 6.2% receiving placebo. This threshold is aligned with kidney disease: Improving Global Outcomes (KDIGO) guidance. The findings were observed alongside supportive care, with sodium-glucose co-transporter 2 (SGLT2) inhibitor use reported in 65.8% of participants.
Both secondary endpoints were also met. Serum galactose-deficient IgA1 (Gd-IgA1) decreased by 77.4% from baseline with povetacicept, compared with a 9.1% increase with placebo, representing a 79.3% reduction versus placebo (P<0.0001).
Among participants with hematuria at baseline, 85.1% receiving povetacicept achieved resolution, compared with 23.4% receiving placebo, a difference of 61.7 percentage points (P<0.0001).
Safety and Patient Treatment Preferences
Povetacicept was generally well tolerated during the reported follow-up, with most adverse events described as mild to moderate. Upper respiratory tract infections occurred in 18.3% of participants receiving povetacicept versus 11.4% receiving placebo. Nasopharyngitis occurred in 9.7% versus 12.4%, respectively, while injection-site reactions occurred in 14.5% versus 2.2%.
No serious adverse events related to povetacicept, deaths or opportunistic infections were reported. No participants discontinued treatment because of infections. Anti-drug antibodies were observed, with no reported impact on efficacy or the risk profile.
Vertex also presented a qualitative study involving 25 US adults with IgAN. After reviewing pictures and short videos of injection devices, 96% preferred the characteristics of an autoinjector over a prefilled syringe, while 80% preferred dosing every four weeks over weekly administration. These findings reflect stated preferences rather than actual treatment adherence or clinical outcomes.
Mechanism and Regulatory Outlook
Povetacicept is an investigational engineered fusion protein that inhibits BAFF and APRIL, cytokines involved in B-cell activation, differentiation and survival. By targeting both pathways, the drug is designed to reduce upstream immune activity implicated in IgAN.
The US Food and Drug Administration (FDA) has accepted Vertex’s biologics license application (BLA) for potential accelerated approval in adults with IgAN. The Prescription Drug User Fee Act (PDUFA) target action date is November 30, 2026. If approved, Vertex plans to offer povetacicept as a low-volume subcutaneous autoinjector administered at home every four weeks.
The company is also evaluating povetacicept in primary membranous nephropathy and generalized myasthenia gravis. In addition, it announced PAVANT (NCT07890909), a Phase 3b, open-label, single-arm study examining patient experience with autoinjector administration in adults with IgAN.
Clinical Interpretation
The RAINIER findings demonstrate a substantial, statistically significant reduction in proteinuria, accompanied by improvements in Gd-IgA1 and hematuria. The results are consistent with the rationale for dual BAFF/APRIL inhibition and are notable given the use of supportive care, including SGLT2 inhibitors, in the trial population.
However, the Week 36 results remain interim findings based primarily on surrogate endpoints. They do not yet establish that povetacicept slows long-term kidney function decline or prevents kidney failure. The higher rate of injection-site reactions and the need for longer-term safety follow-up also warrant attention. The small patient-preference study provides preliminary evidence about device acceptability, not proof of improved adherence.
The planned Week 104 eGFR slope analysis will be important in determining whether the observed proteinuria reduction translates into sustained kidney protection. Until the FDA reaches its decision, povetacicept remains investigational, and its potential clinical benefit must be distinguished from its demonstrated interim efficacy.
Reference
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026. Vertex Pharmaceuticals, October 23, 2026.
Jonathan Barratt, Ph.D et al, Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy, New England Journal of Medicine, Published October 23, 2026, DOI: 10.1056/NEJMoa2608682
Evaluation of Efficacy of Povetacicept in Adults with Immunoglobulin A Nephropathy (IgAN), ClinicalTrials.gov ID NCT06564142
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.